OCT 03, 2016 02:38 PM PDT

Investigation Finds 80% of Chinese Clinical Trial Data are Fraud

WRITTEN BY: Xuan Pham
A quality control survey of clinical trials in China has revealed gross misconduct in how the data for these trials were handled. The investigation alleges that more than 80 percent of data in these clinical trials were manipulated, doctored, and outright fabricated.

Chinese clinical trials lose credibility | Image: pixabay.com

Led by the Chinese State Food and Drug Administration (SFDA), the investigation reviewed data from over 1,600 clinical trials. These involved trials set to receive regulator approval for mass production. The expose was covered by the Economic Information Daily newspaper.

In the expose, SFDA found that more than 80 percent of the data showed scientific dishonesty and corruption at nearly every level. This included deletion of records for adverse events associated with treatments, and massaging data into desired outcomes.

More egregiously, the investigation found that the results of some clinical trials were concocted even before the study began.

This is a "breach of duty by supervision departments and malpractice by pharmaceutical companies, intermediary agents and medical staff," the State Food and Drug Administration (SFDA) said in its report, highlighting deliberate deceit at all levels. Even third party agencies such as contract research organizations whose jobs are to manage and inspect clinical trial facilities were found to be fraudulent and cited as “accomplices in data fabrication due to cutthroat competition and economic motivation.”

Clinical data fabrication is apparently a systemic problem that’s “an open secret even before the inspection,” said an unnamed source in the newspaper.
 


The problem may boil down to competition. And in a market where every pharmaceutical company is trying to earn approval to mass market a Western drug for profit, competition seems to have sabotaged scientific and ethical integrity.

"The domestic market for Western pharmaceuticals in China is either confined to very straightforward generic products that have been around for a long time ... or revolves around joint-venture pharmaceutical manufacture with foreign companies," said Luo Liang, a healthcare professional to Radio Free Asia.

"Either that, or Chinese pharmaceutical factories get hold of the formula for certain drugs whose patents have expired," said Luo Liang. "There are no new drugs in development in the same way that there are overseas."

To Liang and others, the degree of fraud in the Chinese clinical trials is wholly unsurprising and could potentially point to other aspects of Chinese science. "It's not just the medicines," said Mai Ke, a rights activist in Guangdon. "In China, everything is fake, and if there's a profit in pharmaceuticals, then someone's going to fake them too."

But perhaps international scrutiny of this problem will prompt swift reforms in how clinical trials will be conducted and inspected in the future in China.
 
Additional sources: Radio Free Asia, Science Alert
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
APR 25, 2018
Clinical & Molecular DX
APR 25, 2018
Why is dementia going unnoticed in hospitals?
A study in the UK showed that while the rate of diagnosis for dementia is improving, more than a third of all dementia patients still go undiagnosed. The n...
APR 29, 2018
Genetics & Genomics
APR 29, 2018
CRISPR Can Now Edit Genes Outside of the Cell
The CRISPR/Cas9 gene-editing tool was made from an immune defense system used by bacteria. Scientists have found it has many applications....
MAY 23, 2018
Clinical & Molecular DX
MAY 23, 2018
Rapidly Screening Genes in 'Living Test Tubes'
Diagnosing rare disorders is often extremely challenging. Now scientists have developed a new tool for that purpose....
JUN 12, 2018
Cell & Molecular Biology
JUN 12, 2018
Loss of Brain Lesions may Indicate Worsening MS
New research could help doctors determine how severe a case of multiple sclerosis will become....
JUN 23, 2018
Clinical & Molecular DX
JUN 23, 2018
Algorithm-Based Blood Test Diagnoses Autism
As a developmental disorder, autism spectrum disorders (ASD) can be diagnosed as early as 18 to 24 months of age, but often the diagnosis does not come unt...
JUL 12, 2018
Cardiology
JUL 12, 2018
Heart Attacks and Improving Heart Regeneration
A recent study has found that treatment with the protein, VEGF-C, improves healing and recovery of heart function after a heart attack....
Loading Comments...